Paul Hastings Advises Ligand Pharmaceuticals on Its $739 Million Acquisition of XOMA Royalty

Paul Hastings LLP advised leading royalty aggregator Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) on a definitive agreement to acquire biotechnology royalty aggregator XOMA Royalty Corporation (Nasdaq: XOMA) for a total equity value of approximately $739 million.

Partners Andrew Goodman (M&A), Brad Bondi (Litigation; SEC; Public Company Advisory) and Sean Donahue (Public Company Advisory) led the Paul Hastings team, which included partner Brandon Bortner and of counsel Ryan Brewer (Public Company Advisory); partners Eric Schiele and Ben Stein, of counsel Olivier Souleres, and associates Kuai Yu, Shannon Kelly and Shriya Bollampally (M&A); partners Andrew Davis and Joe Opich and associate Michael Pelle (Tax); partner Jason Ertel and associate Steph Lao (Executive Compensation, Benefits and ERISA); partners Brad Bondi and Ronald Anguas and of counsel Neil Schumacher and Nick Griepsma (Litigation); partner Todd Schneider and associate Jordan Hill (IP); partner Joshua Soven and of counsel Catherine Kordestani (Antitrust); partner Holly Snow and associate Daniil Shamelo (Finance); and partner Peter Lindsay (FDA/Regulatory).

More details can be found here.

About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.